At a glance
- Originator Novartis
- Class Antiasthmatics; Antiplatelets
- Mechanism of Action Thromboxane A2 receptor antagonists; Thromboxane synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Thrombosis
Most Recent Events
- 27 Apr 1995 Discontinued-Preclinical for Asthma in USA (Unknown route)
- 27 Apr 1995 Discontinued-Preclinical for Thrombosis in USA (Unknown route)